Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06551415

Dabigatran Versus Apixaban in Cerebral Venous Thrombosis

Dabigatran Versus Apixaban in Cerebral Venous Thrombosis, a Randomized Controlled Trial

Sponsor: Kafrelsheikh University

Conditions Cerebral Venous Sinus Thrombosis

Interventions Apixaban 5MG Dabigatran Etexilate 150mg

Updated 2 times since 2024 Last updated: Aug 9, 2024 Started: Aug 1, 2021 Primary completion: Sep 1, 2024 Completion: Oct 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cerebral Venous Sinus Thrombosis and is currently actively recruiting participants. Kafrelsheikh University leads this study, which shows 2 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE3

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kafrelsheikh University

Data source: Kafrelsheikh University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kafr ash Shaykh, Egypt